Study guide
2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)
Certified Addictions Registered Nurse - Advanced Practice CARN-AP
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice
About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care
2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance
1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene
3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone
2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)
4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal
3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications
5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)
4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen
6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders
5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds
7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions
6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management
8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions
7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice
9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning
8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy
10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines
9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)
11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications
10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP
12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing
11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation
13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy
12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine
14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction
13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education
15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition
14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol
16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder
15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support
17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations
16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders
18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy
17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education
19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse
18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM
20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)
19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching
21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)
20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation
22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)
21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction
2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)
Key Takeaways Explain This Topic AI
Sublocade utilizes the ATRIGEL delivery system (PLGA polymer in N-methyl-2-pyrrolidone) injected strictly subcutaneously into the abdomen, where it solidifies into a biodegradable depot upon contact with interstitial fluid.
Sublocade requires a minimum of 7 days of transmucosal buprenorphine stabilization (8–24 mg/day) and an initiation regimen of two consecutive monthly 300 mg loading doses followed by 100 mg monthly maintenance.
Brixadi employs FluidCrystal lipid technology, offering both weekly (8–32 mg) and monthly (64–128 mg) subcutaneous dosing across multiple anatomical sites without mandatory cold storage.
Extended-release naltrexone (Vivitrol, 380 mg gluteal IM every 4 weeks) demands a strict 7- to 10-day opioid-free window (14 days for methadone/buprenorphine) verified by negative urine toxicology and a naloxone challenge test.
Vivitrol carries a critical post-treatment loss-of-tolerance warning; patients who relapse to prior opioid doses face an extreme risk of fatal respiratory depression.
Last updated: September 2026
2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)
Core Clinical Competency: The APRN must evaluate clinical candidacy, navigate complex delivery system pharmacokinetics, execute safe injection protocols, and manage treatment transitions for long-acting injectable (LAI) buprenorphine formulations and extended-release naltrexone to optimize long-term recovery and mitigate overdose mortality.
1. Sublocade (Extended-Release Subcutaneous Buprenorphine)
Sublocade is a monthly subcutaneous injectable buprenorphine formulation designed to eliminate the daily adherence burden and plasma level fluctuations associated with sublingual dosing.
The ATRIGEL Delivery System & Depot Kinetics
Composition: Sublocade utilizes the proprietary ATRIGEL delivery system , comprising a biodegradable copolymer of poly(DL-lactide-co-glycolide) (PLGA, 50:50 ratio) dissolved in a water-miscible, biocompatible organic solvent, N N N -methyl-2-pyrrolidone (NMP) .
Mechanism of Solidification: When injected into subcutaneous adipose tissue, the water-miscible NMP solvent rapidly diffuses into the surrounding interstitial aqueous fluid. This phase inversion causes the PLGA polymer to precipitate and solidify into a distinct, gelatinous-to-firm subcutaneous depot encapsulating the buprenorphine.
Sustained Zero-Order Release: The depot slowly hydrolyzes via non-enzymatic ester cleavage into endogenous lactic acid and glycolic acid over weeks to months, providing stable, sustained buprenorphine plasma concentrations ( > 2 to 3 ng/mL >2\text{ to }3\text{ ng/mL} > 2 to 3 ng/mL ) that achieve ≥70% to 80% mu-opioid receptor occupancy .
Clinical Candidacy & Mandatory Run-In Period
Indication: Treatment of moderate-to-severe Opioid Use Disorder in adult patients.
Mandatory Stabilization Period: Patients must initiate treatment with a transmucosal buprenorphine-containing product (sublingual film or tablet) and achieve dose stabilization for at least 7 days (typically 8 mg to 24 mg daily) prior to Sublocade administration. This run-in confirms clinical tolerability and rules out hypersensitivity.
Standard Dosing Regimen
Loading Phase: 300 mg subcutaneous injection once monthly for the first two months (Month 1 and Month 2).
Rationale for Loading: Two 300 mg doses are required to rapidly attain steady-state therapeutic plasma concentrations ( > 2 ng/mL >2\text{ ng/mL} > 2 ng/mL ) within the first 48 to 72 hours, preventing early craving breakthrough or illicit opioid use.
Maintenance Phase: 100 mg subcutaneous injection once monthly starting at Month 3.
Dose Up-Titration: If a patient on 100 mg maintenance exhibits persistent cravings, withdrawal breakthrough, ongoing illicit opioid use, or has a high body mass index (accelerated clearance), the maintenance dose may be increased to 300 mg monthly .
Injection Interval: Administered every 28 days (minimum window of 26 days between injections). Sublocade Standard Monthly Dosing Flow:
- [Day -7 to Day 0: SL Buprenorphine Stabilization (8-24 mg/d)]
- │
- ▼
- [Month 1: Sublocade 300 mg SC (Abdomen)]
- │
- ▼ (Wait 28 days)
- [Month 2: Sublocade 300 mg SC (Abdomen)]
- │
- ▼ (Wait 28 days)
- [Month 3+: Sublocade 100 mg SC Monthly Maintenance]
- *(May increase to 300 mg monthly for persistent cravings)*
- Administration Technique & Black Box Warnings
STRICTLY ABDOMINAL SUBCUTANEOUS INJECTION ONLY: Injected into the subcutaneous tissue of the abdominal wall between the transpyloric and transtubercular planes, rotating between quadrants.
Caution
BLACK BOX WARNING — RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION: Sublocade must NEVER be administered intravenously or intramuscularly. Intravenous injection causes the ATRIGEL polymer to instantly solidify upon contact with aqueous blood, forming an occlusive intravascular foreign body that causes massive pulmonary embolism, vascular occlusion, catastrophic tissue necrosis, and immediate death.
REMS Program Distribution: Distributed exclusively through a restricted Risk Evaluation and Mitigation Strategy (REMS) program. Sublocade is shipped directly from a specialty pharmacy to the healthcare facility and must never be dispensed directly to the patient .
Cold Chain Storage & Equilibration: Must be refrigerated at 2°C to 8°C (36°F to 46°F). Prior to administration, the prefilled syringe must sit at room temperature for at least 15 to 30 minutes to allow the viscous formulation to warm, facilitating injection and reducing injection-site pain.
2. Brixadi (Subcutaneous Buprenorphine with FluidCrystal Technology)
Approved by the FDA in 2023, Brixadi provides significant therapeutic flexibility, offering both weekly and monthly formulations across diverse anatomical injection sites.
The FluidCrystal Drug Delivery Platform
Biophysical Mechanism: Brixadi utilizes FluidCrystal lipid technology consisting of phosphatidylcholine and soy lysophosphatidylcholine dissolved in ethanol.
In Situ Nanostructured Gel: Injected as a low-viscosity liquid through a fine 23-gauge needle. Upon contact with aqueous interstitial fluid in subcutaneous tissue, it self-assembles into an inverted hexagonal liquid-crystalline nanostructured gel that traps buprenorphine and releases it at a consistent, controlled rate as the lipid matrix undergoes slow enzymatic biodegradation.
Room-Temperature Storage: Unlike Sublocade, Brixadi is stored at room temperature (20°C to 25°C) and requires no refrigeration or pre-injection warming , streamlining clinic workflow.
Dosage Forms & Anatomical Administration Sites
Brixadi offers a broad spectrum of prefilled, single-dose glass syringes equipped with an automatic safety needle guard:
Formulation Available Strengths Clinical Conversion from Daily Sublingual Buprenorphine
Brixadi Weekly 8 mg, 16 mg, 24 mg, 32 mg • ≤6 mg/day SL → \rightarrow → 8 mg weekly ; • 8–10 mg/day SL → \rightarrow → 16 mg weekly ; • 12–16 mg/day SL → \rightarrow → 24 mg weekly ; • 18–24 mg/day SL → \rightarrow → 32 mg weekly (maximum)
Brixadi Monthly 64 mg, 96 mg, 128 mg • 8–10 mg/day SL → \rightarrow → 64 mg monthly ; • 12–16 mg/day SL → \rightarrow → 96 mg monthly ; • 18–24 mg/day SL → \rightarrow → 128 mg monthly (maximum); no monthly strength is offered for SL ≤6 mg/day
Unique Clinical Advantages of Brixadi
Diverse Anatomical Injection Sites: In addition to the abdomen , Brixadi is FDA-approved for subcutaneous injection into the buttock, thigh, and upper arm . Rotating across these sites dramatically reduces injection-site reactions and accommodates patients with abdominal scarring or lipodystrophy.
Direct Weekly Initiation: In buprenorphine-naive patients or those not yet stabilized, Brixadi Weekly can be initiated after a single test dose of sublingual buprenorphine (e.g., 4 mg SL) to verify tolerability, completely eliminating the mandatory 7-day sublingual run-in required by Sublocade .
Granular Dose Matching: The multiple weekly and monthly dose strengths allow the APRN to match the patient's exact sublingual dose requirement without forcing a generic 300 mg/100 mg transition.
3. Extended-Release Injectable Naltrexone (Vivitrol)
Vivitrol is an extended-release injectable suspension of the pure opioid antagonist naltrexone, approved for both Opioid Use Disorder and Alcohol Use Disorder.
Receptor Mechanism & Delivery Platform
Pure Opioid Antagonism: Naltrexone binds competitively to mu-opioid receptors with high affinity and zero intrinsic efficacy . It acts as a silent competitive antagonist, completely blocking full and partial agonists from binding.
Microsphere Matrix: Formulated as 380 mg of naltrexone embedded within biodegradable poly(D,L-lactide-co-glycolide) (PLG) microspheres suspended in an aqueous diluent. Following deep intramuscular injection, microspheres undergo gradual degradation, maintaining therapeutic antagonist levels for 4 weeks .
Dosing & Administration: 380 mg administered strictly as a deep intramuscular (IM) gluteal injection every 4 weeks (alternating gluteal muscles each month). Must be administered using the customized 1.5-inch or 2.0-inch safety needle provided in the kit. Never administer subcutaneously or intravenously.
Mandatory Opioid-Free Clearance Window
Because naltrexone possesses high mu-affinity and zero intrinsic efficacy, administering Vivitrol in the presence of circulating full or partial agonists triggers catastrophic, violent precipitated withdrawal.
- Opioid Class Previously Used Mandatory Minimum Opioid-Free Window
- Short-Acting Opioids (Heroin, IR Oxycodone, Fentanyl, Morphine) 7 to 10 days absolute abstinence
- Long-Acting Opioids (Methadone, Buprenorphine, LA Morphine) 14 days absolute abstinence
- The Naloxone Challenge Test Protocol
Before administering Vivitrol, the APRN must objectively confirm the absence of circulating opioids:
Urine Toxicology: Confirm a negative instrumented urine drug screen for all opioids, including synthetic fentanyls, buprenorphine, and methadone.
Naloxone Challenge Administration: Administer 0.4 mg to 0.8 mg naloxone subcutaneously or intravenously (or 0.8 mg IM).
Clinical Observation (20–30 Minutes): Observe the patient closely for emergent withdrawal signs:
Objective signs: Pupillary dilation, diaphoresis, piloerection, tachycardia, tremors, yawning.
Subjective symptoms: Abdominal cramping, nausea, myalgias, acute craving.
Interpretation: If any withdrawal signs appear, the test is positive —do NOT give Vivitrol; re-evaluate in 24 to 48 hours. If no symptoms occur after 30 minutes, the test is negative .
Oral Naltrexone Trial (Optional Clinical Pearl): Many clinicians administer an oral naltrexone trial (25 mg to 50 mg PO daily for 1 to 3 days) following a negative naloxone challenge as an added safety step before injecting the 30-day depot.
- 4. Loss of Tolerance & Hepatic Safety Monitoring
- Black Box Warning: Loss of Opioid Tolerance & Fatal Overdose Risk
During Vivitrol treatment, continuous blockade of mu-opioid receptors results in the complete loss of acquired physiological opioid tolerance. Downstream receptor upregulation and cellular re-sensitization restore the patient to an opioid-naive state. Vivitrol Loss-of-Tolerance Fatality Mechanism:
- [Patient on Vivitrol: Mu Receptors 100% Blocked]
- │
- ▼
- [Patient Loses Acquired Opioid Tolerance Over 1-3 Months]
- │
- ▼
- ┌──────────────────┴──────────────────┐
- ▼ ▼
- [Patient Attempts to Override Blockade] [Patient Misses Next Injection / Relapses]
- Consumes massive opioid doses to overcome Resumes opioid use at doses previously
receptor antagonism. If opioid outlasts tolerated during active addiction.
antagonist levels -> FATAL OVERDOSE. -> RAPID FATAL RESPIRATORY APNEA.
Warning
Critical Patient Education Point: Patients must be explicitly educated that if they attempt to overcome the Vivitrol receptor blockade by ingesting large quantities of opioids, or if they relapse after missing an injection or discontinuing treatment, they will die from respiratory arrest at doses they previously tolerated .
Hepatic Monitoring & Safety Parameters
Metabolism: Naltrexone is metabolized primarily via non-cytochrome P450 hepatic enzymes (aldo-keto reductase) into its primary active metabolite, 6-beta-naltrexol .
Hepatotoxicity Warnings: Early trials with high-dose oral naltrexone (300 mg/day) revealed hepatocellular injury. While Vivitrol at 380 mg monthly rarely causes significant hepatotoxicity, baseline liver function tests (LFTs) are mandatory.
Clinical Thresholds: Exercise clinical caution if baseline AST or ALT exceeds 3 to 5 times the upper limit of normal (ULN) . Vivitrol is strictly contraindicated in patients with acute hepatitis, hepatic decompensation, or end-stage liver disease .
5. Comparative Matrix: Long-Acting Injectables in Addictions Practice
- Parameter Sublocade Brixadi (Monthly) Vivitrol
- Active Molecule Buprenorphine Buprenorphine Naltrexone
- Pharmacological Class Mu Partial Agonist Mu Partial Agonist Pure Mu Antagonist
- Delivery Technology ATRIGEL (PLGA in NMP) FluidCrystal (Lipid-based) PLG Microsphere Suspension
- Route & Site SC only: Abdomen strictly SC: Abdomen, thigh, arm, buttock IM only: Gluteal strictly
Pre-Induction Run-In ≥7 days transmucosal bup None (or single test dose for weekly) 7–10 days opioid-free (14d methadone)
Needle Gauge / Size 19G or 20G, 5/8-inch 23G, 1/2-inch 20G, 1.5-inch or 2.0-inch
Storage Requirement Refrigerated (2°C–8°C); warm 15–30m Room temperature (20°C–25°C) Refrigerated (2°C–8°C); warm to room temp
Overdose Risk on Relapse Low (protective ceiling effect) Low (protective ceiling effect) EXTREMELY HIGH (loss of tolerance)
Dual AUD/OUD Indication OUD only OUD only Both AUD and OUD
6. Clinical Decision Algorithm: Selecting LAI Formulations Clinical Algorithm for Long-Acting Injectable Selection:
- [Patient with Moderate-to-Severe OUD]
- │
- ┌───────────────────────────┴───────────────────────────┐
- ▼ ▼
- [Patient Desires Opioid Agonist] [Patient Highly Motivated for
- (Suppresses cravings/withdrawal) Total Opioid Abstinence]
- │ (e.g., licensed professionals,
- │ criminal justice mandate, co-occurring AUD)
- ▼ │
- [Assess Prior Buprenorphine Tolerability] ▼
- │ [Extended-Release Naltrexone]
- ┌────┴────────────────────────┐ • Must be opioid-free 7-10 days
- ▼ ▼ • Negative UDT + Naloxone challenge
- [Stabilized on SL Bup ≥7 days] [Bup-Naive / Immediate Transition] • Administer Vivitrol 380 mg IM gluteal
- │ │ • Extensive loss-of-tolerance warning
- ├─────────────────────────────┘
- ▼
[Choose Sublocade vs. Brixadi]:
- Sublocade: 300 mg monthly x 2, then 100 mg monthly (Abdominal SC only; cold-chain storage)
- Brixadi: Weekly (8-32 mg) or Monthly (64-128 mg) across Abdomen, Arm, Thigh, Buttock
- (Room-temperature storage, smaller injection volume, flexible dosing)